Lead program to treat patients with GI Diseases & Disorders
Our lead program includes five drug candidates for GI therapeutics:
- SYGN305 for Radiation Mucositis and Radiation Proctitis
- SYGN399 for Radiation Syndrome
- SYGN313 for both acute and chronic inflammation of the GI tract, such as Crohn’s disease and inflammatory bowel disease (IBD)
- SYGN309 for GI Infection
- SYGN303 for distal intestinal obstructive syndrome (DIOS)
Synedgen is developing SYGN303 as a potential treatment for distal intestinal obstructive syndrome (DIOS), in which thick mucus causes blockage in the intestine. DIOS is a GI complication associated with cystic fibrosis, for which there are no targeted or approved drugs.